| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/00007890-200203270-00016 |
| P8608 | Fatcat ID | release_gz7yzzrbmzfonbnk27bleajwny |
| P698 | PubMed publication ID | 11923693 |
| P2093 | author name string | Bruce Kaplan | |
| John M Kovarik | |||
| Stefan Vitko | |||
| Barry D Kahan | |||
| Christiane Rordorf | |||
| Hélio Tedesco Silva | |||
| Jacque Dantal | |||
| Robert Boger | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | kidney transplantation | Q740909 |
| P304 | page(s) | 920-925 | |
| P577 | publication date | 2002-03-01 | |
| P1433 | published in | Transplantation | Q15730500 |
| P1476 | title | Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range | |
| P478 | volume | 73 |
| Q35236076 | Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study. |
| Q35047701 | Alterations in glucose metabolism by cyclosporine in rat brain slices link to oxidative stress: interactions with mTOR inhibitors |
| Q57793005 | Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine |
| Q44343584 | Clinical development of an everolimus pediatric formulation: relative bioavailability, food effect, and steady-state pharmacokinetics |
| Q33358752 | Clinical pharmacokinetics of everolimus |
| Q44632267 | Differential effect of cyclosporine A and SDZ RAD on neointima formation of carotid allografts in apolipoprotein E-deficient mice |
| Q58805821 | Drug-Induced Hematological Cytopenia in Kidney Transplantation and the Challenges It Poses for Kidney Transplant Physicians |
| Q33360240 | Everolimus |
| Q51805179 | Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients. |
| Q38646743 | Everolimus immunosuppression in kidney transplantation: What is the optimal strategy? |
| Q33357118 | Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure |
| Q54568641 | Everolimus is a potent inducer of erythroid differentiation and gamma-globin gene expression in human erythroid cells. |
| Q46909282 | Everolimus versus azathioprine in maintenance lung transplant recipients: an international, randomized, double-blind clinical trial. |
| Q34546358 | Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies |
| Q57119713 | Everolimus-induced loss of wound strength can be prevented by a short postoperative delay in its administration |
| Q44781575 | Everolimus/cyclosporine interactions on bile flow and biliary excretion of bile salts and cholesterol in rats |
| Q36441466 | Everolimus: a review of its use in renal and cardiac transplantation |
| Q36521866 | Everolimus: an immunosuppressive agent in transplantation. |
| Q37992135 | Everolimus: preventing organ rejection in adult kidney transplant recipients |
| Q35711463 | Experience with everolimus |
| Q38214871 | Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes |
| Q46468654 | Graft function, cardiovascular risk factors, and sex hormones in renal transplant recipients on an immunosuppressive regimen of everolimus, reduced dose of cyclosporine, and basiliximab. |
| Q80783177 | Higher incidence of acute rejection in renal transplant recipients with low everolimus exposure |
| Q36029868 | Immunosuppressive drug monitoring - what to use in clinical practice today to improve renal graft outcome |
| Q35563912 | Immunosuppressive therapy in liver transplantation |
| Q44663048 | Influence of delayed initiation of cyclosporine on everolimus pharmacokinetics in de novo renal transplant patients |
| Q46542215 | Influence of everolimus on steady-state pharmacokinetics of cyclosporine in maintenance renal transplant patients |
| Q40159228 | Laryngeal transplantation: research, clinical experience, and future goals |
| Q45985298 | Limited sampling strategies for the estimation of sirolimus daily exposure in kidney transplant recipients on a calcineurin inhibitor-free regimen. |
| Q36763206 | Long-term cross-validation of everolimus therapeutic drug monitoring assays: the Zortracker study |
| Q44412683 | Mycophenolic acid is a potent inhibitor of the expression of tumour necrosis factor‐ and tumour necrosis factor‐receptor superfamily costimulatory molecules |
| Q36099424 | Novel therapies in transplantation |
| Q37763757 | Once-a-day administration of everolimus, cyclosporine, and steroid after renal transplantation: a review of the rationale |
| Q38747967 | Optimizing everolimus exposure when combined with calcineurin inhibitors in solid organ transplantation |
| Q36006086 | Pharmacokinetic principles of immunosuppressive drugs. |
| Q44444375 | Pharmacokinetics of an Everolimus-Cyclosporine Immunosuppressive Regimen Over the First 6 Months After Kidney Transplantation |
| Q42284856 | Suppression of cytomegalovirus-specific CD8(+)T cells by everolimus |
| Q26823023 | Systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitors |
| Q24246340 | Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients |
| Q35711449 | The evolving experience using everolimus in clinical transplantation |
| Q38115702 | The role of mechanistic target of rapamycin (mTOR) complexes signaling in the immune responses |
| Q45171050 | Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling |
| Q30983921 | Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data |
| Q46702760 | Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients |
| Q57793035 | Wound events in kidney transplant patients receiving de novo everolimus: a pooled analysis of three randomized controlled trials |
| Q38209973 | mTOR inhibitors and renal allograft: Yin and Yang. |
Search more.